Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Ratio (2016 - 2025)

Lineage Cell Therapeutics' Equity Ratio history spans 16 years, with the latest figure at 0.39 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 43.4% year-over-year to 0.39; the TTM value through Dec 2025 reached 0.39, down 43.4%, while the annual FY2025 figure was 0.39, 43.4% down from the prior year.
  • Equity Ratio reached 0.39 in Q4 2025 per LCTX's latest filing, up from 0.23 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2021 to a low of 0.23 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.63, with a median of 0.62 recorded in 2023.
  • Peak YoY movement for Equity Ratio: increased 11.7% in 2022, then plummeted 65.41% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.52 in 2021, then rose by 11.7% to 0.58 in 2022, then increased by 5.55% to 0.61 in 2023, then rose by 10.79% to 0.68 in 2024, then crashed by 43.4% to 0.39 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Equity Ratio are 0.39 (Q4 2025), 0.23 (Q3 2025), and 0.52 (Q2 2025).